A comprehensive phase 2b trial has been conducted to evaluate the effectiveness of Glecirasib in patients with KRAS G12C-mutated non-small-cell lung cancer (NSCLC). This study involved a collaborative effort from numerous prestigious institutions across China and the United States, including the National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital in Beijing, Fudan University Shanghai Cancer Center, and Jacobio Pharmaceuticals Co., Ltd., among others.
Key Highlights:
- Objective: To assess the efficacy and safety of Glecirasib in treating NSCLC patients with the KRAS G12C mutation.
- Methodology: The trial was conceptualized and designed by Yuankai Shi, with data collection, analysis, and interpretation carried out by a team of researchers from various institutions.
- Collaboration: The study saw participation from over 40 hospitals and research centers, highlighting a significant collaborative effort in the field of oncology.
- Outcome: The manuscript detailing the trial's findings was developed, reviewed, and edited by a core team, including Yuankai Shi, Andrea Wang-Gillam, and others, ensuring a comprehensive analysis of the data collected.
This trial represents a pivotal step forward in the search for effective treatments for KRAS G12C-mutated NSCLC, a subtype of lung cancer that has historically been challenging to treat. The involvement of such a wide array of institutions underscores the global effort to combat this disease and the potential of Glecirasib as a therapeutic option.
